TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — E Split Corp. (TSX: ENS and ENS.PR.A) (the “Fund”) is pleased to announce that a distribution for September 2026 will be payable to Class A shareholders as follows:

Record Date Payable Date Distribution Per
Equity Share
September 30, 2026 October 15, 2026 $0.14

The Fund also announces that the third quarter distribution of 2026 will be payable to preferred shareholders as follows:

Record Date Payable Date Distribution Per
Preferred Share
September 30, 2026 October 15, 2026 $0.175


The equity and preferred shares both trade on the Toronto Stock Exchange under the respective symbols ENS and ENS.PR.A.

For further information, please visit our website at www.middlefield.com or contact our Sales and Marketing Department at 1.888.890.1868.

This press release contains forward-looking information. The forward-looking information contained in this press release is based on historical information concerning distributions and dividends paid on the securities of issuers historically included in the portfolio of the Fund. Actual future results, including the amount of distributions paid by the Fund, may differ from the monthly distribution amount. Specifically, the income from which distributions are paid may vary significantly due to: changes in portfolio composition; changes in distributions and dividends paid by issuers of securities included in the Fund’s portfolio from time to time; there being no assurance that those issuers will pay distributions or dividends on their securities; the declaration of distributions and dividends by issuers of securities included in the portfolio will generally depend upon various factors, including the financial condition of each issuer and general economic and stock market conditions; the level of borrowing by the Fund; and the uncertainty of realizing capital gains.  The risks, uncertainties and other factors that could influence actual results are described under “Risk Factors” in the Fund’s prospectus and other documents filed by the Fund with the Canadian securities regulatory authorities. The forward-looking information contained in this press release constitutes the Fund’s current estimate, as of the date of this press release, with respect to the matters covered hereby. Investors and others should not assume that any forward-looking statement contained in this press release represents the Fund’s estimate as of any date other than the date of this press release.

Sampo plc, stock exchange release, 23 September 2026 at 4:40 pm EEST

Announcement of Sampo plc’s results and Annual General Meeting in 2027

Sampo plc will publish a Financial Statement Release for 2026 on 4 February 2027. Sampo will report its results on following days during 2027:

– 5 May 2027: Interim Statement for the period January–March 2027

– 11 August 2027: Half-Year Financial Report for the period January–June 2027

– 3 November 2027: Interim Statement for the period January–September 2027

The financial results will be published at approximately 8:30 am Finnish time (6:30 am UK time).

The Financial Statements and the Board of Directors’ Report, including Corporate Governance Statement and Sustainability Statement, and the Remuneration Report for Governing Bodies for 2026 will be published at www.sampo.com/year2026 during week 12.

The Annual General Meeting of Sampo plc is planned to be held on Wednesday, 21 April 2027. A shareholder may request that a matter falling under the authority of the General Meeting of Shareholders shall be placed on the agenda of the AGM. To this effect, a written request should be sent to the Board of Directors on Wednesday, 17 February 2027, at the latest.

Sampo Group’s Solvency and Financial Condition Report (SFCR) will be published in May 2027.

SAMPO PLC
Investor Relations and Group Communications

For further information, please contact:

Mirko Hurmerinta
Interim Head of Investor Relations
tel. +358 10 516 0032

Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com

23 September 2026

PayPoint plc (“the Company”)

Notifications of transactions by Persons Discharging Managerial Responsibilities

(together “PDMRs”)

The PayPoint plc Share Incentive Plan

This announcement sets out details of the monthly acquisition of Partnership Shares and the corresponding award of Matching Shares under the Company’s Share Incentive Plan (“SIP”), effected on 22 September 2026 for those PDMRs who participate in the SIP, including the following Executive Directors:

Executive Director Partnership Shares Purchased
Date: 22 September 2026
Purchase Price: £6.3250
Matching Shares Awarded
Date: 22 September 2026
Award Price: £6.3250
Nicholas Wiles 20 20
David Robert Harding 20 20

        
The Notification of Dealing Forms can be found below.

This Notification is made in accordance with the requirements of the UK Market Abuse Regulation.

ENQUIRIES:        
PayPoint plc           

Sophie Line, on behalf of Indigo Corporate Secretary Limited, Company Secretary
+44 (0)7927 132060

Steve O’Neill, Chief Marketing and Corporate Affairs Officer
+44 (0)7919 488066

LEI: 5493004YKWI8U0GDD138

https://www.paypointbusiness.com/corporate

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name
  1. Julian Coghlan
  2. Simon Coles
  3. Ben Ford
  4. David Robert Harding
  5. Samantha Holden
  6. Mark Latham
  7. Tanya Murphy
  8. Stephen O’Neill
  9. Christopher Paul
  10. Anthony Sappor
  11. Josephine Toolan
  12. Katy Wilde
  13. Nicholas Wiles
2 Reason for the notification
a) Position/status
  1. PDMR
  2. PDMR
  3. PDMR
  4. Chief Financial Officer
  5. PDMR
  6. PDMR
  7. PDMR
  8. PDMR
  9. PDMR
  10. PDMR
  11. PDMR
  12. PDMR
  13. Chief Executive Officer
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name PayPoint plc
b) LEI 5493004YKWI8U0GDD138
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 0.3611 pence each
ISIN: GB00BVMTNR93
b) Nature of the transaction Shares purchased pursuant to the PayPoint plc Share Incentive Plan.
c)

Price(s) and volume(s)

  Price(s) Volume(s)
1. £6.3250 20
2. £6.3250 20
3. £6.3250 20
4. £6.3250 20
5. £6.3250 20
6. £6.3250 20
7. £6.3250 20
8. £6.3250 20
9. £6.3250 20
10. £6.3250 20
11. £6.3250 20
12. £6.3250 20
13. £6.3250 20
d)

Aggregated information

– Volume
– Price
– Total

  Aggregate Volume(s) Price(s) Aggregate Total
1. 20 £6.3250 £126.50
2. 20 £6.3250 £126.50
3. 20 £6.3250 £126.50
4. 20 £6.3250 £126.50
5. 20 £6.3250 £126.50
6. 20 £6.3250 £126.50
7. 20 £6.3250 £126.50
8. 20 £6.3250 £126.50
9. 20 £6.3250 £126.50
10. 20 £6.3250 £126.50
11. 20 £6.3250 £126.50
12. 20 £6.3250 £126.50
13. 20 £6.3250 £126.50
e) Date of the transaction 22 September 2026
f) Place of the transaction London Stock Exchange, Main Market (XLON)

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name
  1. Julian Coghlan
  2. Simon Coles
  3. Ben Ford
  4. David Robert Harding
  5. Samantha Holden
  6. Mark Latham
  7. Tanya Murphy
  8. Stephen O’Neill
  9. Christopher Paul
  10. Anthony Sappor
  11. Josephine Toolan
  12. Katy Wilde
  13. Nicholas Wiles
2 Reason for the notification
a) Position/status
  1. PDMR
  2. PDMR
  3. PDMR
  4. Chief Financial Officer
  5. PDMR
  6. PDMR
  7. PDMR
  8. PDMR
  9. PDMR
  10. PDMR
  11. PDMR
  12. PDMR
  13. Chief Executive Officer
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name PayPoint Plc
b) LEI 5493004YKWI8U0GDD138
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 0.3611 pence each
ISIN: GB00BVMTNR93
b) Nature of the transaction Matching shares awarded pursuant to the PayPoint plc Share Incentive Plan.
c)

Price(s) and volume(s)

  Price(s) Volume(s)
1. £6.3250 20
2. £6.3250 20
3. £6.3250 20
4. £6.3250 20
5. £6.3250 20
6. £6.3250 20
7. £6.3250 20
8. £6.3250 20
9. £6.3250 20
10. £6.3250 20
11. £6.3250 20
12. £6.3250 20
13. £6.3250 20
d)

Aggregated information

– Volume
– Price
– Total

  Aggregate Volume(s) Price(s) Aggregate Total
1. 20 £6.3250 £126.50
2. 20 £6.3250 £126.50
3. 20 £6.3250 £126.50
4. 20 £6.3250 £126.50
5. 20 £6.3250 £126.50
6. 20 £6.3250 £126.50
7. 20 £6.3250 £126.50
8. 20 £6.3250 £126.50
9. 20 £6.3250 £126.50
10. 20 £6.3250 £126.50
11. 20 £6.3250 £126.50
12. 20 £6.3250 £126.50
13. 20 £6.3250 £126.50
e) Date of the transaction 22 September 2026
f) Place of the transaction London Stock Exchange, Main Market (XLON)

MIAMI BEACH, FL, Sept. 23, 2026 (GLOBE NEWSWIRE) — Cuentas, Inc. (OTCQB: CUEN) today announced a strategic Power-as-a-Service (PaaS) and Colocation Services Agreement with Power Upp USA, Inc. (“PWRU”) for a proposed West Texas Bitcoin mining operation designed to utilize electricity generated from methane and associated gas produced in connection with oil-field operations.

The initiative expands Cuentas’ participation in the Bitcoin ecosystem by combining energy recovery, onsite power generation, Bitcoin mining and the Company’s Bitcoin Mobile wireless service, creating a connection between Cuentas’ telecommunications customers and its digital-asset infrastructure.

Turning Stranded Energy into Productive Power

The proposed project is designed to capture and utilize methane and associated gas at or near the oil-production site, where transportation of the gas or access to conventional grid power may be limited. By generating electricity onsite, the project is intended to reduce reliance on conventional utility power while putting an underutilized energy resource to productive use.

Federal environmental regulations, including the EPA’s New Source Performance Standards for the oil and natural gas sector, address methane emissions and associated gas from covered oil and gas operations. Cuentas believes that projects that recover and beneficially use associated gas can provide both economic and environmental value, subject to applicable regulatory requirements and project-specific circumstances.

Cuentas does not characterize the project as zero-emission. Rather, its potential environmental benefit is based on the productive utilization of associated gas that might otherwise have limited economic value or require alternative handling under applicable regulations.

Revenue, Competitive Energy Economics and Local Benefits

Phase 1 of the project should provide Cuentas with approximately 1.5 BTC (Bitcoins) per month in revenue. The current average BTC price over $86,000 should yield revenue of approx. $130,000 per month.

The PaaS Colocation project will also provide lower-cost power than many conventional Bitcoin mining operations that depend upon higher-cost grid electricity. Combining these financial benefits should product monthly profit of up to $43,000. Cuentas is planning to use these BTC profits to subsidize and/or reward its customers with enhanced mobile services, cyber-security & VPN.

Additionally, the public should welcome this ecologically beneficial project as it will create jobs, significantly reduce the gas burned off at the oilfields and no public utility will be used. This project provides a win-win solution for the oilfield producers, the local economy and does not cause public complaints as do so many data center projects currently in the news.

The proposed deployment in Phase 1 contemplates 1 containerized mining unit, approximately 2.4 megawatts of contracted power capacity and approximately 420 operational ASIC miners, plus 12 spares. Phase 2 is scheduled for up to up to 10 containerized mining units, approximately 24 megawatts of contracted power capacity and approximately 4,200 operational ASIC miners with 120 spares when fully deployed. At current Bitcoin prices, Phase 2 should yield revenue of approx. $1.3 Million per month with profit of approx. $430,000. Deployment is expected to occur in stages, allowing Cuentas to evaluate actual operating performance and economics as the project progresses.

“We believe this project represents an exciting opportunity to connect energy recovery, digital infrastructure and our telecommunications strategy,” said Shalom Arik Maimon, CEO of Cuentas. “Our objective is to utilize an otherwise stranded energy resource to generate electricity onsite while building a potentially efficient Bitcoin mining platform that can contribute to recurring revenue and support our broader digital-asset strategy.”

“We are pleased to partner with Cuentas as it advances its Digital-asset strategy,” said Matt Inan, Chief Executive Officer of Power Upp USA, Inc. “This agreement reflects the value of pairing dependable, scalable power infrastructure with flexible colocation services for high-performance compute and digital-asset applications. We look forward to supporting Cuentas with a solution designed to help it deploy efficiently and scale in line with its operational requirements.”

Bitcoin Mobile: Connecting Wireless Service with Bitcoin Rewards

Cuentas is developing Bitcoin Mobile, a next-generation mobile service designed to combine high-quality nationwide wireless connectivity with subsidies and/or Bitcoin rewards, sourced from its BTC profits.

“Bitcoin Mobile is aiming to become a worldwide company that provides both US e-SIMs and MULTI-IMSI e-SIMs (local operations in foreign countries) designed to give consumers a practical way to receive indirect benefits from the Bitcoin economy while receiving the high-quality wireless service they already need,” added Maimon. “Combined with our planned Bitcoin mining activities, we believe Cuentas can participate across multiple levels of the Bitcoin ecosystem—from telecommunications and consumer rewards to energy-efficient digital-asset infrastructure.”

Staged Development

Cuentas intends to evaluate actual power availability, generator performance, mining output, operating costs and revenue generation during staged deployment before proceeding with subsequent phases.

The Company cautions investors that the contemplated mining project does not guarantee future Bitcoin production or profitability. Actual results will depend on Bitcoin prices, network difficulty, ASIC efficiency, power availability, methane supply, generator performance, operating expenses, regulatory requirements and other factors.

About Cuentas, Inc.

Cuentas, Inc. (OTCQB: CUEN) is developing financial technology, telecommunications and digital infrastructure solutions designed to create technology-enabled services and new sources of recurring revenue. Through its majority-owned subsidiary, World Mobile LLC, Cuentas is expanding its participation in telecommunications, Bitcoin mining and blockchain-related infrastructure. Cuentas believes these complementary businesses have the potential to create new consumer services and additional sources of shareholder value.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of U.S. federal securities laws. All statements other than statements of historical fact are forward-looking statements, including statements regarding the Company’s plans and expectations relating to its SEC reporting status, any potential listing on a major U.S. exchange  or relisting on the Nasdaq Capital Market, business strategy, future operations, and prospects.

Forward-looking statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control. Actual results may differ materially from those expressed or implied by any forward-looking statement. Important factors that could cause actual results to differ materially include, among others, the Company’s ability to continue to meet SEC reporting obligations, , to obtain necessary approvals, to fund its operations, and to execute its business strategy, as well as other risks described in the Company’s filings with the SEC.

Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:

Shalom Arik Maimon – CEO
Cuentas, Inc.
235 Lincoln Road, Suite 210
Miami Beach, FL 33139

info@cuentas.com
www.cuentas.com

– Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders –

REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that it has initiated the process to market and sell the remaining assets associated with the Company’s former biosimilars business (the “Legacy BioSim Assets”). The Company has retained Oppenheimer & Co. Inc. (“Oppenheimer”) to serve as its financial advisor in connection with the sale. Parties interested in the opportunity should direct inquiries to the Oppenheimer contacts listed below.

“We are pleased to be working with a bank of Oppenheimer’s caliber to market our legacy biosimilars assets,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “We are confident that this will result in a robust process with global reach to solicit interest and bids for this attractive asset package, for the benefit of our shareholders.”

As previously announced on August 17, 2026, the Company declared a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed pro rata to stockholders of record of the Company’s common stock as of September 30, 2026 (the “Record Date”), with distribution occurring on October 7, 2026. CVR holders are entitled to receive their pro rata share of any net cash proceeds, and the net cash value of any other consideration, actually received by the Company from third parties in connection with the sale of the Legacy BioSim Assets or as licensing fees under any licensing agreement covering the Legacy BioSim Assets.

The Legacy BioSim Assets include:

        • Patents and other intellectual property
        • Royalties under an existing license agreement
        • Cell lines
        • Related materials, including laboratory notebooks, regulatory filings, and product samples

To be eligible to receive the CVRs, an investor must be a stockholder of record of the Company’s common stock as of the Record Date. Investors should contact their brokers with any questions regarding their holder status as of the Record Date.

Further Information

The terms of the CVRs are set forth in, and the CVRs are governed by, the Contingent Value Rights Agreement by and between the Company and Equiniti Trust Company, LLC, as rights agent (the “CVR Agreement”). The Company’s stockholders are also encouraged to review the FAQ concerning the CVRs. The CVR Agreement and the FAQ were included as exhibits to the Form 8-K that the Company filed with the SEC on August 17, 2026, and are available on the Investors & Media – Shareholder Services section of the Company’s website.

Stockholders who hold their shares through a broker should note that the crediting of CVRs may be subject to the practices and procedures of such intermediary. In certain circumstances, including where shares are rehypothecated or loaned out, different mechanics may apply, and it is possible that an investor will not receive the CVRs if its shares are rehypothecated or loaned out as of the Record Date. Stockholders are encouraged to contact their broker directly for confirmation and for additional information regarding the timing and manner in which the CVRs will be reflected in their accounts.

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma while advancing the development of its two pipeline candidates in combination with LOQTORZI, and additionally through strategic partnerships. The Company has global rights to both clinical stage-candidates and plans to execute ex-U.S. licensing deals as the clinical data supports such transactions.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated distribution of the CVRs, the expected record date and distribution date, the proposed process to market and sell the Legacy BioSim Assets, the timing and outcome of that process, and the value, timing, and amount, if any, of proceeds that may become distributable to CVR holders. These statements are based on Coherus’ current expectations and involve substantial risks and uncertainties that could cause actual results to differ materially, including the risk that no sale or licensing transaction involving the Legacy BioSim Assets is consummated, that any transaction that is consummated is on terms less favorable than anticipated, and that CVR holders may receive little or no payment under the CVRs. These and other risks are described in Coherus’ filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Coherus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Oppenheimer Contact Information:
Stefan Loren, Ph.D.
Managing Director — Oppenheimer & Co. Inc.
Stefan.Loren@opco.com

Arif Sheikh
Managing Director — Oppenheimer & Co. Inc.
Arif.Sheikh@opco.com

Coherus Contact Information:
For Investors & Media:
Carrie Graham
Vice President, Investor Relations and Advocacy
IR@coherus.com

LANGHORNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a company with a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience, today announced dial-in details for its previously announced investor update call to be held on September 24, 2026, at 4:15 p.m. Eastern Time.

Investor Update Call Details

Date: September 24, 2026
Time: 4:15 p.m. Eastern Time
Live Call: 1-833-309-3473 (U.S. Toll Free) or 1-785-838-9251 (International)
Conference ID: NEXGEL

For interested individuals unable to join the conference call, a replay will be available through October 1, 2026, by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following access code to access the replay of the call: 11162643.

The call will provide investors with an update on the Company’s operational progress, commercialization initiatives, and other corporate matters.

About NEXGEL, INC.

NEXGEL, through its Bionx Surgical division, is a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience. Bionx has a strong offering of products including Biovance (human amniotic membrane allograft), Biovance 3L (tri-layer human amniotic membrane allograft), Interfyl (human connective tissue matrix), SilverSeal (antimicrobial hydrogel wound dressing), and an expansive opthalmic portfolio of placental derived ocular allografts (LUCENT, single layer, RADIANT, dual layer, and VIVID, triple layer). Additionally, NEXGEL is a provider of healthcare, beauty, and over the counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. In addition to the above, NEXGEL brands include Hexagels®, Turfguard®, Kenkoderm® and Silly George®. NEXGEL also has strategic contract manufacturing relationships with leading consumer healthcare companies.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, statements regarding the timing, content, and conduct of the anticipated investor update call. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@kcsa.com

Not for distribution to United States newswire services or for dissemination in the United States. Not an offer of securities for sale in the United States

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Fredonia Mining Inc. (“Fredonia” or the “Company”) (TSXV: FRED) is pleased to announce that it has closed its previously announced “bought deal” private placement, pursuant to which it has issued an aggregate of 17,692,400 common shares of the Company (the “Offered Shares”) at a price of C$0.65 per Offered Share for aggregate gross proceeds of C$11,500,060, which includes the full exercise of the underwriters’ option (collectively, the “Offering”).

The Company intends to use the net proceeds from the Offering for the exploration and advancement of the Company’s El Dorado Monserrat Project in Santa Cruz province, Argentina, and for general corporate and working capital purposes, all as further described in the offering document relating to the Offering.

The Offering was completed by a syndicate of underwriters led by ATB Cormark Capital Markets (the “Lead Underwriter”), as lead underwriter and sole bookrunner, and which included Canaccord Genuity Corp. (together with the Lead Underwriter, the “Underwriters” and each individually, an “Underwriter”). In consideration for the services provided by the Underwriters in connection with the Offering, the Company paid the Underwriters a cash commission equal to 6.0% of the gross proceeds of the Offering, other than in respect of gross proceeds from sales to purchasers on the President’s List, for which a cash commission equal to 3.0% of the gross proceeds was payable.

Directors and executive officers of the Company subscribed for a total of 500,000 Offered Shares in the Offering for aggregate gross proceeds of C$325,000. The participation of insiders in the Offering constitutes a “related party transaction”, within the meaning of the TSX Venture Exchange (the “Exchange”) Policy 5.9 and Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company relied on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(b) and 5.7(1)(b) of MI 61-101 in respect of the related party participation in the Offering, which will be described in further detail in a material change report to be filed in connection with the Offering that will be accessible under the Company’s profile on SEDAR+ at www.sedarplus.ca. The material change report relating to the Offering will be filed less than 21 days prior to the closing date of the Offering. The Company believes the shorter period was reasonable and necessary in the circumstances, as the typical lifecycle for a transaction of this nature is significantly less than 21 days and the Company desired to act on an available financing opportunity.

In accordance with National Instrument 45-106 Prospectus Exemptions (“NI 45-106”), the Offered Shares were issued to purchasers resident in certain provinces of Canada pursuant to the “listed issuer financing exemption” (the “Listed Issuer Financing Exemption”) under Part 5A.2 of NI 45-106, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. The Offered Shares issued to purchasers resident in Canada pursuant to the Listed Issuer Financing Exemption are not subject to a four-month statutory hold period in Canada. The Offered Shares were also offered in the United States by way of private placement pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and in certain other jurisdictions outside of Canada and the United States on a private placement or equivalent basis, in each case in accordance with all applicable laws. The Offered Shares were issued to purchasers outside of Canada pursuant to an exemption from the prospectus requirements in Canada available under OSC Rule 72-503 – Distributions Outside Canada and, accordingly, the Offered Shares issued to purchasers outside of Canada are not subject to a four-month statutory hold period in Canada. The Offered Shares sold to officers and directors of the Company (as described above) are subject to a four-month hold period pursuant to the rules of the Exchange, expiring January 24, 2027.

The Offering remains subject to final approval of the Exchange.

The securities described herein have not been, and will not be, registered under the U.S. Securities Act, or any U.S. state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the “United States” or to “U.S. persons” (as such terms are defined in Regulation S under the U.S. Securities Act), absent registration under the U.S. Securities Act and all applicable U.S. state securities laws or in compliance with an exemption therefrom. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.‎

Update on Warrant Amendment Transaction

Pursuant to a news release dated December 17, 2025, the Company announced an intention to amend the exercise price of 4,818,932 outstanding warrants to purchase common shares at a price of $1.40 per common share (in the case of each of the price and amount, on an effective, “post-consolidation” basis) to $0.45 per common share. The reduction remained subject to warrantholder and Exchange approvals. As the Company has since the date of the announcement been able to complete financing activity at a higher price per share in order to fund its operations and work programs at the EDM Project, the Company announces it will withdraw its application and intention to proceed with the price reduction. The warrants will remain outstanding and be exercisable in accordance with their terms at a price of $1.40 per share until April 27, 2027.

About Fredonia

Fredonia holds gold and silver license areas totaling approximately 64,000 ha in the prolific Deseado Massif geological region in the Province of Santa Cruz, Argentina, including its flagship advanced EDM project (approximately 33,500 ha) located close to AngloGold Ashanti’s Cerro Vanguardia gold-silver mine (which produced approximately 180,000 ounces of gold during the twelve months ended June 30, 2026*), the El Águila project (approximately 9,100 ha), and the Hornia project (approximately 21,500 ha).

* Source: AngloGold Ashanti plc’s 2025 Form 20-F and Q2 2026 Earnings Release: Operating Statistics. The twelve-month production figure was calculated from the reported production of 179,000 ounces of gold in 2025, less 94,000 ounces produced during the six months ended June 30, 2025, plus 95,000 ounces produced during the six months ended June 30, 2026. Scientific and technical information concerning the Cerro Vanguardia mine has been obtained from publicly available disclosure by AngloGold Ashanti plc and has not been independently verified by the Company’s Qualified Person. Information concerning Cerro Vanguardia is not necessarily indicative of the mineralization, Mineral Resources, or Mineral Reserves on, or the economic potential of, the EDM Project.

For further information: Please visit the Company’s website at www.fredoniamanagement.com or contact: Estanislao Auriemma, Chief Executive Officer, Direct +54 91 149 980 623, Email: estanislao.auriemma@gmail.com.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. “Forward-looking information” includes, but is not limited to, statements with respect to activities, events or developments that the Company expects or anticipates will or may occur in the future, including, without limitation, the anticipated use of the net proceeds of the Offering; the anticipated receipt of all necessary approvals in respect of the Offering, and the intention to abandon the Company’s application to proceed with a reduction in price to outstanding warrants exercisable at an effective price of $1.40 per common share. Generally, but not always, forward-looking information and statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof.

In disclosing the forward-looking information in this release, Fredonia has applied certain factors and assumptions that are based on Fredonia’s current beliefs as well as assumptions made by and information currently available to Fredonia including, among other things, that the Company will use the net proceeds of the Offering as anticipated; and that the Company will receive all necessary approvals in respect of the Offering. Although Fredonia considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking information in this release is subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking information.

Readers are cautioned not to place undue reliance on forward-looking information. Fredonia does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by law.

The expanded partnership delivers a complete, behind-the-meter distributed compute solution for residential deployment at gigawatt scale, built into new home communities from the ground up

SAN FRANCISCO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, and SPAN, the leader in intelligent home energy management, today announced a partnership expansion to accelerate AI compute capacity by combining home energy systems with distributed compute infrastructure. Under the partnership, Sunrun will provide home solar and battery storage to help power SPAN’s XFRA distributed data center solution, accelerating deployed compute capacity.

The partnership combines Sunrun’s home energy products, financing, and installation and service network with SPAN’s XFRA distributed compute node and orchestration capabilities to deliver a scalable, low-cost, low-latency compute solution that can be deployed faster than traditional data centers.

“This partnership expansion with SPAN puts customers first, ensuring that they directly benefit in multiple ways from their participation in this powerful distributed AI solution,” said Sunrun CEO Mary Powell. “By pairing home energy generation and storage with XFRA compute nodes, we are unlocking new economic value for our customers and for Sunrun, while also solving certain speed-to-power constraints that would otherwise limit AI deployment.”

Under the partnership, SPAN and Sunrun will partner with leading homebuilders and begin deployments in new construction residential communities in Texas and other specified markets, enabling distributed AI infrastructure to be built into communities from the ground up. Sunrun’s battery-plus-solar systems will maintain reliable electricity for both the homes and the XFRA compute nodes, while preventing the overloading of local distribution infrastructure—allowing SPAN to maximize node deployment.

“Teaming up with Sunrun solves one of the main bottlenecks for distributed AI compute: power generation and transmission constraints,” said Arch Rao, founder and CEO of SPAN. “We can now drastically increase our penetration of XFRA compute nodes by pairing them with Sunrun energy systems to deliver cost-effective AI compute capacity at unprecedented speed while also reducing compute cost for certain AI applications.”

At no cost to the builder or the homeowner, and without increasing the purchase price of the home, each host customer will receive a smart electrical panel paired with a multi-battery storage and solar system through a pre-paid lease. Customers will also receive whole-home backup power and ongoing compensation for hosting the XFRA compute node.

SPAN’s XFRA platform utilizes liquid-cooled NVIDIA GPUs that are managed through SPAN’s XFRA Secure Orchestration Layer, which intelligently schedules AI workloads based on latency requirements and real-time energy availability at each home.

In addition to providing capacity for the compute nodes and local power infrastructure, Sunrun will enroll the home batteries in its grid service programs, growing Sunrun’s market-leading distributed power plant fleet.

Together, Sunrun and SPAN represent the only end-to-end platform for residential AI compute, combining the nation’s largest residential energy platform with XFRA’s distributed compute network to bring distributed compute capacity online at the speed and scale the AI buildout demands.

About Sunrun
Sunrun Inc. (Nasdaq: RUN) is America’s largest provider of home battery storage, solar, and home-to-grid power plants. As the pioneer of home energy systems offered through a no-upfront-cost subscription model, Sunrun empowers customers nationwide with greater energy control, security, and independence. Sunrun supports the grid by providing on-demand dispatchable power that helps prevent blackouts and lowers energy costs. Learn more at www.sunrun.com.

About SPAN
SPAN is on a mission to enable a more efficient and affordable energy future. The company began by reinventing the electrical panel and continues to transform grid-edge energy infrastructure through combined hardware and software innovation. The SPAN product portfolio includes five smart electrical panel models, SPAN Edge (the intelligent service point), XFRA (the distributed data center), EV charging solutions, and the SPAN Home App. SPAN delivers energy management and advanced power controls that unlock greater grid utilization, benefiting homeowners, builders, utilities, and data center developers with lower costs and faster speed to power. For more information, go to www.span.io.

Sunrun Media Contact
Wyatt Semanek
Sr. Director, Corporate Communications
press@sunrun.com

SPAN Media Contact
press@span.io

Investor & Analyst Contact
Patrick Jobin
SVP, Deputy CFO & Investor Relations Officer
investors@sunrun.com

THIO-104 advances toward key 2027 interim survival analysis

CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal’s National Authority of Medicines and Health Products (INFARMED) to begin screening patients for its ongoing pivotal Phase 3 THIO-104 clinical trial in non-small cell lung cancer (NSCLC).

Spain and Portugal represent important European markets for NSCLC, with an estimated 30,000 new cases annually across the two countries. Spain has a substantial lung cancer burden associated with historical tobacco exposure, with lung cancer incidence among women continuing to rise. In Portugal, NSCLC accounts for approximately 82% of lung cancer cases, the highest proportion reported among five European populations evaluated in a comparative study.

“Expanding THIO-104 into Spain and Portugal represents another important step in the execution of our pivotal Phase 3 program,” said Vlad Vitoc, M.D., Chairman and Chief Executive Officer of MAIA. “Clinical trial participation can provide patients with access to investigational therapies in markets where access to newly approved lung cancer treatments has historically lagged. By establishing THIO-104 sites in Spain and Portugal, we are broadening access to a potentially important new treatment option for patients with advanced NSCLC who have progressed following standard of care treatments.”

To date, THIO-104 has enrolled 65 NSCLC patients resistant to chemotherapy and checkpoint inhibitor treatments at 28 clinical sites in 6 European countries and 10 sites in Taiwan. Among the six European countries, sites in Hungary, Poland, and Turkey are actively enrolling and dosing patients from populations with the highest lung cancer incidence and mortality rates in Europe and globally.1

MAIA targets 100 patients dosed in THIO-104 by year-end 2026 and expects to have sufficient survival data to conduct an interim data analysis in 2027.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com


1 Sources: Global Cancer Observatory (GLOBOCAN), European Cancer Information System (ECIS), World Cancer Research Fund

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.